http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016096872-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-625 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-90 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5fc4d1cffca41f6717936ade2b5a377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb3897a4b37fd3cf18c5e1aa0739dfc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_089d2f61d632a03a19d5ca3c8580e4fe |
| publicationDate | 2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2016096872-A1 |
| titleOfInvention | Methods for producing peptides using engineered inteins |
| abstract | The present invention provides a method for producing peptides by recombinant means. The peptides are expressed as part of a fusion protein comprising the target peptide and an engineered intein. The invention also provides the engineered inteins, fusion proteins comprising these, and DNA constructs coding for these fusion proteins. Upon thiol-induced cleavage of the fusion protein the carboxy-terminal a-thioester of the target peptide is obtained. The carboxy-terminal ct-thioester can in principle react with any nucleophile and the strategy therefore allows a wider range of carboxy-terminal modifications such as chemical ligation, bioconjugation, or amidation. The engineered inteins of the present invention are minimized in size and has a cysteine mutation in the position corresponding by alignment to position 3 of Mxe GyrA intein (SEQ ID NO:1) leading to increased expression levels of the fusion protein and higher yields of the isolated target peptide, thus making the method of the invention suitable for production scale. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9771412-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016122417-A1 |
| priorityDate | 2013-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.